knowledge -WSS

knowledge

author：knowledge 2025-09-29 16:34:47 - browse：8676

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Why a market frenzy over new weight loss drugs defies logic

hotspot

WSS

Meadows told special counsel he could not recall Trump ever declassifying Mar

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Roche acquires Telavant from Roivant, adding experimental IBD treatment

ADCs take center stage as promising cancer treatments

Why a market frenzy over new weight loss drugs defies logic

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

State Dept. review finds Biden bears some blame for Afghanistan failures

Results on Novartis prostate cancer therapy could expand its use

Psychedelics group wrestles with new pharma identity

Can U.S. cancer drug shortages be fixed?

ChatGPT in medicine: STAT answers readers' burning questions

Roche acquires Telavant from Roivant, adding experimental IBD treatment

leisure time

STAT Summit: The economic case for universal basic health care

FDA advisory panel to debate high blood pressure devices

Study on Amgen’s bispecific immunotherapy produces positive data

As obesity drug market grows, telehealth companies court payers

Roche drug slashes death risk in early

Questions loom on AstraZeneca cancer drug as safety concerns ebb

hotspot

hotspot

focus

focus